BCL2 interacting protein 3 pseudogene 29Genealiases: []
Q-omics provides the consensus-scored BNIP3P29 profile across patient tissues and cancer cell-line models. BNIP3P29 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, BNIP3P29 is differentially expressed in 1, with the highest sampling consensus in COAD. Additionally, BNIP3P29 RNA expression shows 6,606 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, COAD, and STAD as cancer lineages where BNIP3P29 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BNIP3P29 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BNIP3P29 survival associations across molecular data types. BNIP3P29 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BNIP3P29 RNA expression–survival associations across cancer types. High BNIP3P29 expression shows unfavorable associations in KIRC, UCEC, ACC and STAD, but favorable associations in KIRP and GBM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KIRC as the clearest survival context for BNIP3P29 RNA expression.
This table summarizes BNIP3P29 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for BNIP3P29. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BNIP3P29 shows lower tumor expression in COAD. The COAD box plot shows higher BNIP3P29 RNA expression in normal versus tumor tissue (log2 FC = −0.040, t-test p = .033).
This table shows molecular features associated with BNIP3P29 in patient tissues and cancer cell lines. In patient samples, BNIP3P29 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
